droxidopa has been researched along with Parkinson Disease, Secondary in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lakke, JP; Muskiet, FA; Staal-Schreinemachers, AL; Teelken, AW; van den Berg, GA; Wolthers, BG | 1 |
| Hirose, Y; Kajita, S; Mizukawa, K; Ogawa, N; Ohara, S; Watanabe, Y | 1 |
| Narabayashi, H | 1 |
| Kondo, T; Nagatsu, T; Narabayashi, H; Yokochi, F | 1 |
4 other study(ies) available for droxidopa and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Catecholamine metabolism during additional administration of DL-threo-3,4-dihydroxyphenylserine to patients with Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Catecholamines; Dopamine; Droxidopa; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Middle Aged; Parkinson Disease, Secondary; Serine | 1989 |
MPTP-induced parkinsonian model in mice: biochemistry, pharmacology and behavior.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Droxidopa; Levodopa; Mice; Mice, Inbred C57BL; Parkinson Disease, Secondary; Pyridines; Receptors, Muscarinic; Somatostatin | 1987 |
[L-threo-DOPS therapy and parkinsonism].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Antiparkinson Agents; Brain; Dopamine; Droxidopa; Humans; Levodopa; Norepinephrine; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Serine; Stereotaxic Techniques | 1986 |
Clinical effects of L-threo-3,4-dihydroxyphenylserine in cases of parkinsonism and pure akinesia.
Topics: Adult; Aged; Antiparkinson Agents; Droxidopa; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Parkinson Disease, Secondary; Serine; Shy-Drager Syndrome | 1987 |